Navigation Links
New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
Date:9/16/2009

HOERSHOLM, Denmark and SAN DIEGO, California, September 16 /PRNewswire/ --

- Denmark-Based Santaris Pharma A/S Appoints Leading RNA Industry Expert Art Levin Ph.D. as President of US Operations and Chief Development Officer

- Utilizing its Proprietary RNA Chemistry - Locked Nucleic Acid (LNA) -and Drug Discovery Engine, the US Subsidiary Aims to Foster Relationships With New Partners, Increase Visibility With Capital Markets and Attract Leading Scientists

- Santaris Pharma A/S is First Company to Advance a microRNA-Targeted Drug into Human Clinical Trials; SPC3649 Targets miR-122 for the Treatment of Hepatitis C

- Recently Announced Strategic Alliance With Shire Demonstrates LNA is Rapidly Becoming the Chemistry-of-Choice and Adds to the Growing List of mRNA and microRNA Drug Discovery and Development Partnerships That Include Wyeth, GlaxoSmithKline and Enzon for a Range of Diseases

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

Increasing interest, new collaborations and breakthrough advancements utilizing the Company's proprietary RNA-based Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine led Santaris Pharma A/S, headquartered in Denmark, to establish US-based operations in San Diego, California.

To spearhead the US expansion, Santaris Pharma A/S has appointed leading RNA industry expert Arthur A. Levin, PhD, as President of its US operations. In addition, Dr. Levin will hold global responsibility as Vice President and Chief Development Officer
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
2. Californias International Stem Cell Collaborations Must Be Based on Scientific Merit, Consumer Group Says
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
5. Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
6. Research breakthrough will lead to more accurate weather forecasts
7. OMT announces a breakthrough in the development of a novel human antibody platform
8. New drugs faster from natural compounds: A UC San Diego breakthrough
9. Expanding Indianas Breakthroughs in Health Information Technology (Exibhit Indiana): Initiative to Advance the States Health IT National Leadership and Assets Launched to Bring More Awareness to Sector
10. Light sensor breakthrough could enhance digital cameras
11. DNA2.0 Awarded US Patents for Breakthrough Gene Optimization Technology -- Company's Unique Algorithm Enables Expression Yields up to 50 Times Greater than Competing Approaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a ... the relationship of genetics and hypertension at the International Academy of Cardiology ... British Columbia, Canada. The event, which boasts an extensive overview of the latest ...
(Date:8/26/2015)... MIAMI , Aug. 26, 2015  The ... at the University of Miami Miller School of ... its clinical trial to test for the first ... was successfully completed.  This FDA approved Phase I/II ... islet transplantation and is an important first step ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2
... - Index Changes Scheduled to Take Effect with the Market Open on ... ... N.J., May 12 Pharmasset, Inc.,(Nasdaq: VRUS ), a clinical stage ... is pleased to announce that it has been selected to join the,NASDAQ ...
... of different modalities ... imaging platform., SAN DIEGO, and BRUSSELS, Belgium, May ... manufacturer and developer of,intravascular ultrasound (IVUS), functional measurement (FM) ... diagnosis and,treatment of coronary and peripheral vascular disease, announced ...
... YORK and PARSIPPANY, N.J., May 12 ... U.S.-based pharmaceutical company, and,Daiichi Sankyo, Inc. today ... for AZOR(TM)* (amlodipine and olmesartan medoxomil),Daiichi Sankyo,s ... blocker amlodipine besylate and the angiotensin receptor,blocker ...
Cached Biology Technology:Pharmasset Selected to Join the NASDAQ Biotechnology Index 2Pharmasset Selected to Join the NASDAQ Biotechnology Index 3Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 2Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 3Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 4Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 2Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 3Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 4
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... NY Binghamton University researchers recently revived ancient bacteria ... in salt crystals. For decades, geologists have looked ... and wondered whether microbes could be extracted from them. ... in age from thousands to hundreds of millions years ...
... from the Harvard School of Public Health (HSPH) finds that ... a problem of the rich. The findings suggest that the ... already happened in wealthier countries has not yet happened in ... of the American Journal of Clinical Nutrition and ...
... do you do? You probably first move out of the way ... Your brain is able to quickly switch from detecting an object ... a phenomenon called adaptation. A new study in the Nov. ... details the biological basis of this ability for rapid adaptation: neurons ...
Cached Biology News:Researchers kick-start ancient DNA 2Overweight primarily a problem among wealthier women in low- to middle-income countries 2Study reveals neural basis of rapid brain adaptation 2Study reveals neural basis of rapid brain adaptation 3
... AFFINITY PURIFIED GOAT ANTI-MOUSE ... is conjugated with highly ... The antibody has ... human, rat, fetal bovine, ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
Contains L-glutamine....
Biology Products: